CD26+ Th17 cells isolated and expanded from TYRP transgenic mice expressing the TRP-1 T cell receptor that recognizes tyrosinase were adoptively transferred into the tumor-bearing mice, and tumor burden was measured for 128 days, during which sitagliptin treatment was constant. Here, TYRP1 is linked to neoplasm.